美国复发性过敏反应:发作时间与危险因素
基于2015-2017年Clinformatics数据库,采用ICD-10-CM编码分析所有诊疗场景中双相和复发性过敏反应的趋势与危险因素。2016年共19,039例新发过敏反应患者,其中10.6%在12个月内复发;复发最常见诱因为毒液,其次为食物过敏原;<18岁患者、过敏性鼻炎和哮喘患者复发风险更高。
要点
- 复发性过敏反应在初始事件后3天内最常见。
- <18岁患者复发风险高于18-64岁患者(HR 1.53)。
- 过敏性鼻炎和哮喘分别增加复发风险(HR 1.15和1.27)。
核心结论
- 复发性过敏反应在初始事件后3天内、年轻患者(<18岁)以及合并过敏性鼻炎和/或哮喘的患者中更常见。
- 医生应开具肾上腺素自动注射器并教育患者复发的风险。
研究设计与样本
- 使用2015-2017年Clinformatics数据库的回顾性队列研究。
- 纳入2016年新发过敏反应的19,039例患者,随访12个月内复发性过敏反应事件。
- 采用Cox比例风险模型评估复发相关因素,Kaplan-Meier法估计复发时间。
主要发现
- 2016年新发过敏反应患者19,039例,其中2017例在索引日期后12个月内发生复发性过敏反应(10.6%)。
- 复发性过敏反应最常见的诱因为毒液,其次为食物过敏原。
- <18岁患者较18-64岁患者更易发生复发性过敏反应(HR 1.53)。
- 过敏性鼻炎和哮喘患者较无这些合并症者更易发生复发性过敏反应(HR分别为1.15和1.27)。
关键数值与推荐
- 复发性过敏反应定义为索引日期后1年内发生的复发性过敏反应事件。
- 年龄<18岁与复发风险增加相关(HR 1.53)。
- 过敏性鼻炎与复发风险增加相关(HR 1.15)。
- 哮喘与复发风险增加相关(HR 1.27)。
临床怎么用
- 对过敏反应患者应评估复发风险,尤其是<18岁、合并过敏性鼻炎或哮喘者。
- 处方肾上腺素自动注射器并向患者宣教复发风险及早期识别。
- 关注初始事件后3天内的复发风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Studies have not yet examined the trends and risk factors of biphasic and recurrent anaphylaxis in the United States using International Classification of Diseases, tenth revision (ICD-10) CM codes. The goal of this study is to examine the trends of biphasic and recurrent anaphylaxis in all patient care settings (inpatient, outpatient, emergency department, and observation). METHODS: We used the Clinformatics database from 2015 to 2017. Our main outcome measure was recurrent anaphylactic events occurring within 1 year after the initial event. We used Cox proportional hazards modeling to assess the factors associated with recurrent anaphylaxis and the Kaplan-Meier method to estimate time to recurrence. RESULTS: There were a total of 19,039 patients with incident anaphylaxis in 2016 and, of these, 2017 had a recurrent anaphylaxis event in the 12-month period after the index date (10.6%). The most common trigger for recurrent anaphylaxis is venom followed by food allergens. Pediatric patients aged <18 years were more likely to develop recurrent anaphylaxis compared with patients aged 18 to 64 years (hazard ratio [HR], 1.53). Patients with allergic rhinitis and asthma were more likely to develop recurrent anaphylaxis compared to those without these comorbidities (HR, 1.15 and 1.27, respectively). CONCLUSION: This is the first national study using ICD-10 CM codes looking at rates of biphasic and recurrent anaphylaxis in all patient care settings. Recurrent anaphylaxis is more common in the first 3 days after the initial event, in younger patients (<18 years), and in patients with allergic rhinitis and/or asthma. Physicians need to prescribe epinephrine auto-injectors and educate their patients about the risk of recurrence.
引用
- Chaaban MR, Stuart J, Watley D, et al. Recurrent anaphylaxis in the United States: time of onset and risk factors. Int Forum Allergy Rhinol. 2019. PMID: 31774625. doi:10.1002/alr.22502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。